Skip to main content
. 2012 Feb 24;3(5):1154–1158. doi: 10.3892/ol.2012.617

Figure 1.

Figure 1

DFS in the group of patients after curative surgery (n=29), comparing patients receiving EAP with an average dose intensity for the 4 cycles of >90% (n=13) versus <90% (n=16). DFS, disease-free survival; EAP, etoposide/cisplatin/adriamycin.